Gilead donates over 2,000 vials of remdesivir to support WHO-led Ebola treatment trial

Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD

0.00
  • Gilead will donate more than 2,000 vials of intravenous remdesivir for investigational use in the WHO-led PARTNERS filovirus treatment trial.
  • The study targets Bundibugyo virus disease during the ongoing outbreak in the Democratic Republic of the Congo, Uganda.
  • Remdesivir is not approved for filovirus disease treatment in any country; safety and efficacy for Ebola and Marburg, including Bundibugyo, remain unestablished.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief on July 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.